Title: Comparison of Electrolyte Disturbance of Using IntravenousAminophylline Versus Nebulization Salbutamol for ExacerbationAsthma in Surabaya, Indonesia
Abstract: Background: Uncontrolled asthma symptoms will exacerbate asthma. Aminofilin is now rarely used as asthma medication
abroad because it shows major side effects, unlike in Indonesia, which is still widely used with relatively rare side effects
events. Aminophylline have relatively more affordable price compared to salbutamol, the first-line option in the
management of asthma exacerbations requirements. Both of these drugs have a risk of causing electrolyte disturbances,
which could endanger the patients. Considering the individual drug side effects, so it important to study the safety of the
medicine to ascertain whether there are differences in the incidence of electrolyte disturbances by both drugs.
Objective: The main objective of this study was to determine differences in the incidence of electrolyte disturbances in
patients with asthma exacerbations prescribed with aminophylline and salbutamol at a hospital in Surabaya.
Method: This study design is a cross-sectional study of inpatient adult asthma exacerbations in emergency room (ER),
using two groups, namely the group receiving intravenous aminophylline therapy (n = 22), and the group receiving
nebulized salbutamol therapy (n = 21).
Result: There is no significant difference between in intravenous aminophylline anda nebulized salbutamol group. And
there is no significant difference in sodium (p>0,866) and potassium (p>0,470) level in blood as a respon to the asthma
exacerbations treatment by intravenous aminophylline compared to nebulized salbutamol.
Conclusion: Although there was no significant difference in the incidence of electrolyte disturbances in both drugs, but
close monitoring is still needed to prevent any side effects incident.
Publication Year: 2016
Publication Date: 2016-01-01
Language: en
Type: article
Access and Citation
Cited By Count: 4
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot